Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Diabetologia

• Publication date

  2018-01-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00125-017-4535-5PMID 29305624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.

  2018cited by this paper
• Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.

  2018cited by this paper
• Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

  2017cited by this paper
• Branched Chain Amino Acids Are Associated with Insulin Resistance Independent of Leptin and Adiponectin in Subjects with Varying Degrees of Glucose Tolerance

  2017cited by this paper
• Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study

  2017cited by this paper
• Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

  2017cited by this paper
• Insulin and Glucagon: Partners for Life

  2017cited by this paper
• Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.

  2017cited by this paper
• Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels

  2017cited by this paper
• Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.

  2017cited by this paper
• Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation

  2016cited by this paper
• Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

  2016cited by this paper
• Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

  2016cited by this paper
• Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome.

  2015cited by this paper
• Association between insulin resistance and plasma amino acid profile in non-diabetic Japanese subjects

  2015cited by this paper
• Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

  2015cited by this paper
• Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass.

  2015cited by this paper
• Stability of glucagon-like peptide 1 and glucagon in human plasma

  2015cited by this paper
• GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

  2015cited by this paper
• Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion

  2015cited by this paper
• Evidence of Extrapancreatic Glucagon Secretion in Man

  2015cited by this paper
• Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

  2014cited by this paper
• Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia

  2013cited by this paper
• Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

  2012cited by this paper
• Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care

  2012cited by this paper
• A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

  2009cited by this paper
• High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism.

  2009cited by this paper
• Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, &agr; Cell Hyperplasia, and Islet Cell Tumor

  2009cited by this paper
• Glutamate is a positive autocrine signal for glucagon release.

  2008cited by this paper
• Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.

  2007cited by this paper
• α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains.

  2007cited by this paper
• Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test

  2007cited by this paper
• Weight Loss and Non-alcoholic Fatty Liver Disease: Falls In Gamma-Glutamyl Transferase Concentrations are Associated with Histologic Improvement

  2006cited by this paper
• Glucagon secretion in relation to insulin sensitivity in healthy subjects

  2005cited by this paper
• Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease*

  2004cited by this paper
• Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

  2003cited by this paper
• Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome

  2002cited by this paper
• Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans

  2001cited by this paper
• Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures.

  2000cited by this paper
• The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening

  2000cited by this paper
• Factors affecting the stability of L-glutamine in solution.

  1991cited by this paper
• Increased amino acid clearance and urea synthesis in a patient with glucagonoma.

  1990cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Effects of glucagon on plasma amino acids.

  1984cited by this paper
• The Amino Acid-Induced Secretion of Glucagon

  1983cited by this paper
• Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.

  1982cited by this paper
• Amino acid deficiency and the skin rash associated with glucagonoma.

  1979cited by this paper
• Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.

  1978cited by this paper
• Glucagon-stimulating activity of 20 amino acids in dogs.

  1972cited by this paper
• The effect of alanine on glucagon secretion.

  1971cited by this paper

• Is glucagon action altered in steatotic liver disease?

  2026cites this paper
• Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice.

  2025cites this paper
• Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort.

  2025cites this paper
• Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state

  2025cites this paper
• Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon.

  2025cites this paper
• Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

  2025cites this paper
• Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial

  2025cites this paper
• Dynamic multi-omics profiling of islet and gut hormonal secretion and peripheral crosstalk in response to various nutrient loads

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Timing of Glucose Intake Drives Distinct Hepatic Outcomes: Divergent Glucose and Lipid Metabolism.

  2025cites this paper
• Allosteric communication mechanism in the glucagon receptor

  2025cites this paper
• Islet hormones at the intersection of glucose and amino acid metabolism

  2025cites this paper
• Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status

  2025cites this paper
• The neglected PCK1/glucagon (inter)action in nutrient homeostasis beyond gluconeogenesis: Disease pathogenesis and treatment

  2025cites this paper
• Lipid regulation of the glucagon receptor family

  2024cites this paper
• Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes

  2024cites this paper
• Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans

  2024cites this paper
• Comparable glucagon-stimulated amino acid suppression in individuals with and without hepatic steatosis or steatohepatitis.

  2024cites this paper
• Elevations in plasma glucagon are associated with reduced insulin clearance after ingestion of a mixed-macronutrient meal in people with and without type 2 diabetes

  2024influential citation
• Lipid metabolism in MASLD and MASH: From mechanism to the clinic

  2024cites this paper
• Hepatic steatosis-and not type 2 diabetes, body mass index or hepatic fibrosis-associates with hyperglucagonemia in individuals with steatotic liver disease.

  2024cites this paper
• Advances in basic research on glucagon and alpha cells

  2024cites this paper
• Glucagon resistance in individuals with obesity and hepatic steatosis can be measured using the GLUSENTIC test and index.

  2024cites this paper
• Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes

  2024cites this paper
• Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus

  2024cites this paper
• Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease.

  2024cites this paper
• Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence

  2024cites this paper
• Advances in clinical research on glucagon

  2024cites this paper
• Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study

  2024cites this paper
• Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

  2023cites this paper
• Amino acids and the changing face of the -cell

  2023cites this paper
• Altered Glucagon and GLP-1 Responses to Oral Glucose in Children and Adolescents With Obesity and Insulin Resistance

  2023cites this paper
• Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling - a UK Biobank study

  2023influential citation
• Amino acids and the changing face of the -cell

  2023cites this paper
• Mof plays distinct roles in hepatic lipid metabolism under healthy or non-alcoholic fatty liver conditions

  2023cites this paper
• Signs of Glucagon Resistance After a Two-Week Hypercaloric Diet Intervention.

  2023cites this paper
• Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes

  2023influential citation
• Serum alanine transaminase is predictive of fasting and postprandial insulin and glucagon concentrations in type 2 diabetes.

  2023cites this paper
• Pancreatic islet α cell function and proliferation requires the arginine transporter SLC7A2

  2023cites this paper
• 100 years of glucagon and 100 more

  2023cites this paper
• The relationship between glucose and the liver-alpha cell axis – A systematic review

  2023influential citation
• Low Fasting Concentrations of Glucagon in Patients with Very Long-Chain Acyl-CoA Dehydrogenase Deficiency

  2023cites this paper
• Amino acids and the changing face of the α-cell.

  2023cites this paper
• High Protein Diets Improve Liver Fat and Insulin Sensitivity by Prandial but Not Fasting Glucagon Secretion in Type 2 Diabetes

  2022cites this paper
• Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model

  2022cites this paper
• Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network

  2022cites this paper
• Plasma 1,5-anhydro-d-glucitol is associated with peripheral nerve function and diabetic peripheral neuropathy in patients with type 2 diabetes and mild-to-moderate hyperglycemia

  2022cites this paper
• Increased serum cystatin C levels and responses of pancreatic α- and β-cells in type 2 diabetes

  2022cites this paper
• Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia

  2022cites this paper
• High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides

  2022cites this paper
• Bioinformatics study of the potential therapeutic effects of ginsenoside Rf in reversing nonalcoholic fatty liver disease.

  2022cites this paper
• More than meets the islet: Aligning nutrient and paracrine inputs with hormone secretion in health and disease.

  2022cites this paper
• The Liver–α-Cell Axis in Health and in Disease

  2022cites this paper
• Crosstalk Between Insulin- and Glucagon-Receptor Signaling in the Hepatocyte.

  2022cites this paper
• Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight

  2022cites this paper
• Housing-temperature reveals energy intake counter-balances energy expenditure in normal-weight, but not diet-induced obese, male mice

  2022cites this paper
• The past, present, and future physiology and pharmacology of glucagon.

  2022cites this paper
• Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes

  2022cites this paper
• The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease

  2022cites this paper
• Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model

  2022influential citation
• Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.

  2021cites this paper
• Integrated Metabolomics and Lipidomics Analysis Reveal Remodeling of Lipid Metabolism and Amino Acid Metabolism in Glucagon Receptor–Deficient Zebrafish

  2021cites this paper
• Hepatocyte cholesterol content modulates glucagon receptor signalling

  2021cites this paper
• Peptides in the regulation of glucagon secretion.

  2021cites this paper
• Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges

  2021cites this paper
• The liver-alpha-cell axis after a mixed meal and during weight loss in type 2 diabetes

  2021cites this paper
• DMSO_A_294894 991..1010

  2021cites this paper
• Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes

  2021cites this paper
• Deleterious mutation V369M in the mouse GCGR gene causes abnormal plasma amino acid levels indicative of a possible liver–α-cell axis

  2021cites this paper
• The Human Islet: Mini-organ with Mega-impact.

  2021cites this paper
• Glucagon's Metabolic Action in Health and Disease.

  2021cites this paper
• Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus

  2021influential citation
• Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test

  2021cites this paper
• Metabolomic Signature Between Metabolically Healthy Overweight/Obese and Metabolically Unhealthy Overweight/Obese: A Systematic Review

  2021cites this paper
• What is Diabetes Remission?

  2021cites this paper
• Alanine, arginine, cysteine, and proline but not glutamine are substrates for and acute mediators of the liver-alpha cell axis in female mice.

  2020cites this paper
• Pancreatic Hormones

  2020cites this paper
• The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease

  2020cites this paper
• The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels

  2020cites this paper
• A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia

  2020cites this paper
• Counter-regulatory responses to Telfairia occidentalis-induced hypoglycaemia

  2020cites this paper
• Glucagon Receptor Inhibition Reduces Hyperammonemia and Lethality in Male Mice with Urea Cycle Disorder.

  2020cites this paper
• Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

  2020influential citation
• Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

  2020influential citation
• Islet cell dysfunction in patients with chronic pancreatitis

  2020cites this paper
• Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.

  2020cites this paper
• NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

  2020cites this paper
• Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

  2020cites this paper
• The role of α-cells in islet function and glucose homeostasis in health and type 2 diabetes.

  2020cites this paper
• Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.

  2019cites this paper
• Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling.

  2019cites this paper
• A Primary Role for α-Cells as Amino Acid Sensors

  2019cites this paper
• Integrating the inputs that shape pancreatic islet hormone release

  2019cites this paper
• Impacts of low-protein diet on the hippocampal CA1 neurons and learning deficits in rats

  2019cites this paper
• Role of Peptide Hormones in the Adaptation to Altered Dietary Protein Intake

  2019cites this paper
• Glucagon Receptor Signaling and Glucagon Resistance

  2019cites this paper
• Alanine, arginine, and proline but not glutamine are the feed-back regulators in the liver-alpha cell axis in mice

  2019cites this paper
• Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations

  2019cites this paper
• Assessment of Islet Alpha- and Beta-Cell Function

  2019cites this paper
• The liver-alpha cell axis and type 2 diabetes.

  2019cites this paper